Trial Profile
A global, placebo-controlled Phase 2/3 efficacy trial of CoviLiv for COVID-19
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs CDX 005 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 15 Dec 2022 According to a Codagenix media release, Paul Grint will be a great asset to Codagenix as company look to achieve key upcoming milestones, such as completion of this trial.
- 26 Oct 2022 According to a Codagenix media release, dosing has been initiated in this trial
- 26 Oct 2022 Status changed from planning to recruiting as per Codagenix media release.